190 Results for "

CSFs

" in MedChemExpress (MCE) Product Catalog:
Products (190)

190 Results for "CSFs" in MCE Product Catalog:

160
160 Publications Verification
Cat. No.: HY-16749A
CAS No.: 2040295-03-0
Synonyms: PLX-3397 hydrochloride
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .
loading...
    loading...
160
160 Publications Verification
Cat. No.: HY-16749
CAS No.: 1029044-16-3
Synonyms: PLX-3397
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 .
loading...
    loading...
98
98 Cited Publications
Cat. No.: HY-114153A
Purity:  99.88%
Target:  

c-Fms

Research Areas:  

Neurological Disease

PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. PLX5622 hemifumarate demonstrates desirable PK properties in varies animals .
loading...
    loading...
98
98 Cited Publications
Cat. No.: HY-114153
CAS No.: 1303420-67-8
Purity:  99.79%
Target:  

c-Fms

Research Areas:  

Neurological Disease

PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm .
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-12768
CAS No.: 953769-46-5
Purity:  99.83%
Synonyms: BLZ945
Target:  

c-Fms

Research Areas:  

Infection Neurological Disease Cancer

Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research .
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-12768A
CAS No.: 2222138-31-8
Purity:  99.43%
Synonyms: BLZ945 hydrochloride
Target:  

c-Fms

Research Areas:  

Cancer

Sotuletinib (BLZ945) hydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib hydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research. .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-50905
CAS No.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Research Areas:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10204
CAS No.: 728033-96-3
Purity:  98.57%
Target:  

c-Kit VEGFR c-Fms Apoptosis

Research Areas:  

Cancer

OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10408
CAS No.: 623142-96-1
Purity:  99.51%
Target:  

c-Fms VEGFR c-Kit PDGFR

Research Areas:  

Inflammation/Immunology

Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-117244
CAS No.: 1041852-85-0
Purity:  99.57%
Target:  

c-Fms

Research Areas:  

Cancer

AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-109086
CAS No.: 1142363-52-7
Purity:  98.80%
Synonyms: JNJ-40346527; JNJ-527
Target:  

c-Fms

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively . Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99207
CAS No.: 1229575-09-0
Synonyms: KB 003

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12297
CAS No.: 1308672-74-3
Purity:  99.52%
Synonyms: Surufatinib; HMPL-012
Target:  

FGFR VEGFR

Research Areas:  

Cancer

Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109190
CAS No.: 1619931-27-9
Purity:  99.94%
Synonyms: GB002; PK10571
Target:  

PDGFR c-Fms c-Kit

Research Areas:  

Cardiovascular Disease

Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-113649
CAS No.: 1007377-55-0
Purity:  99.95%
Research Areas:  

Cancer

AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-113413
CAS No.: 645-65-8
Purity:  99.56%
Synonyms: Imidazolyl-4-acetic acid
Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABAA receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109052
CAS No.: 1200493-78-2
Purity:  99.77%
Synonyms: JNJ-54861911
Target:  

Beta-secretase

Research Areas:  

Neurological Disease

Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101774
CAS No.: 2095849-04-8
Purity:  98.11%
Target:  

c-Fms

Research Areas:  

Cancer

CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101768
CAS No.: 1802929-43-6
Purity:  99.78%
Target:  

FGFR c-Fms

Research Areas:  

Cancer

PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99134

Target:  

c-Fms

Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis .
loading...
    loading...